title: Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
abstract: The term castration-resistant prostate cancer (CRPC) encompasses a wide variety of patients with different prognoses. The combination of docetaxel and prednisone is considered as the standard first-line chemotherapy. For years, patients progressing on docetaxel have been managed with second- and third-line hormone therapies, re-treatment with docetaxel, or combined mitoxantrone and prednisone. Recently published results of four studies using different drugs: cabazitaxel (CBZ), abiraterone (AA), enzalutamide (ENZ), and radium 223, showed an increased survival in such patients. In this article, authors make some considerations about criteria guiding the choice of a second-line chemotherapy after docetaxel in patients with metastatic CRPC, and propose an algorithm based on scientific evidence and consensus for rational use of cabazitaxel in this scenario.
authors.affiliation: Department of Oncology, Parc Taulí Sabadell Hospital Universitari, Sabadell, Barcelona, Spain. Electronic address: egallardo@tauli.cat.
authors.forename: Enrique
authors.initials: E
authors.lastname: Gallardo
authors.forename: José Ángel
authors.initials: JÁ
authors.lastname: Arranz
authors.forename: José Pablo
authors.initials: JP
authors.lastname: Maroto
authors.forename: Luis Ángel
authors.initials: LÁ
authors.lastname: León
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018450:Disease Progression; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel
keywords: Algorithm; Cabazitaxel; Castration-resistant hormone cancer; Consensus; Docetaxel